Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis.

Pandit L, Mustafa S, Uppoor R, Nakashima I, Takahashi T, Kaneko K.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 27;5(1):e412. doi: 10.1212/NXI.0000000000000412. eCollection 2018 Jan. No abstract available.

2.

Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.

Mehta MU, Uppoor RS, Conner DP, Seo P, Vaidyanathan J, Volpe DA, Stier E, Chilukuri D, Dorantes A, Ghosh T, Mandula H, Raines K, Dhanormchitphong P, Woodcock J, Yu LX.

Mol Pharm. 2017 Dec 4;14(12):4334-4338. doi: 10.1021/acs.molpharmaceut.7b00687. Epub 2017 Nov 7.

PMID:
29076742
3.

Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.

Li L, Wang Y, Uppoor RS, Mehta MU, Farchione T, Mathis MV, Zhu H.

J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):245-262. doi: 10.1007/s10928-017-9513-5. Epub 2017 Feb 18.

PMID:
28214989
4.

Oxidative Stress in Obese Postmenopausal Women: An Additive Burden for Atherosclerosis.

Uppoor RB, Rajesh A, Srinivasan MP, Unnikrishnan B, Holla R.

J Clin Diagn Res. 2015 Dec;9(12):OC03-5. doi: 10.7860/JCDR/2015/16467.6868. Epub 2015 Dec 1.

5.

Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Bartlett JA, Brewster M, Brown P, Cabral-Lilly D, Cruz CN, David R, Eickhoff WM, Haubenreisser S, Jacobs A, Malinoski F, Morefield E, Nalubola R, Prud'homme RK, Sadrieh N, Sayes CM, Shahbazian H, Subbarao N, Tamarkin L, Tyner K, Uppoor R, Whittaker-Caulk M, Zamboni W.

AAPS J. 2015 Jan;17(1):44-64. doi: 10.1208/s12248-014-9701-9. Epub 2014 Nov 25.

6.

Mammographic and sonographic features of fat necrosis of the breast.

Upadhyaya VS, Uppoor R, Shetty L.

Indian J Radiol Imaging. 2013 Oct;23(4):366-72. doi: 10.4103/0971-3026.125619.

7.

An integrated clinical pharmacology approach for deriving dosing recommendations in a regulatory setting: review of recent cases in psychiatry drugs.

Younis IR, Rogers H, Zhang H, Zhu H, Uppoor RS, Mehta MU.

J Clin Pharmacol. 2013 Oct;53(10):1005-9. doi: 10.1002/jcph.118. Epub 2013 Jul 10. Review.

PMID:
23842865
8.

Anatomy of the atlas and axis.

Shaw O, Uppoor R.

BMJ. 2012 Nov 7;345:e7399. doi: 10.1136/bmj.e7399. No abstract available.

PMID:
23135198
9.

Anatomy of the pituitary region.

Shaw O, Uppoor R.

BMJ. 2012 Oct 24;345:e6963. doi: 10.1136/bmj.e6963. No abstract available.

PMID:
23097552
10.

Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.

Stier EM, Davit BM, Chandaroy P, Chen ML, Fourie-Zirkelbach J, Jackson A, Kim S, Lionberger R, Mehta M, Uppoor RS, Wang Y, Yu L, Conner DP.

AAPS J. 2012 Dec;14(4):925-6. doi: 10.1208/s12248-012-9397-7. Epub 2012 Sep 14. No abstract available.

11.

Passive transdermal systems whitepaper incorporating current chemistry, manufacturing and controls (CMC) development principles.

Van Buskirk GA, Arsulowicz D, Basu P, Block L, Cai B, Cleary GW, Ghosh T, González MA, Kanios D, Marques M, Noonan PK, Ocheltree T, Schwarz P, Shah V, Spencer TS, Tavares L, Ulman K, Uppoor R, Yeoh T.

AAPS PharmSciTech. 2012 Mar;13(1):218-30. doi: 10.1208/s12249-011-9740-9. Epub 2012 Jan 4. Review.

12.

Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label.

Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, Mehta M, Lesko L, Temple R, Stockbridge N, Laughren T, Gobburu JV.

Clin Pharmacol Ther. 2011 Sep;90(3):471-4. doi: 10.1038/clpt.2011.149. Epub 2011 Jul 27. No abstract available.

PMID:
21796114
13.

Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging.

Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, Sudeep AB, Muruganandam N, Chaitanya IK, Guruprasad DR.

Trans R Soc Trop Med Hyg. 2010 Jun;104(6):392-9. doi: 10.1016/j.trstmh.2010.01.011. Epub 2010 Feb 19.

PMID:
20171708
14.

CT evaluation of flank pain and suspected urolithiasis.

Alshamakhi AK, Barclay LC, Halkett G, Kukade G, Mundhada D, Uppoor RR, Gawai P.

Radiol Technol. 2009 Nov-Dec;81(2):122-31.

PMID:
19901350
15.

Effect of ethanol on opioid drug permeability through caco-2 cell monolayers.

Volpe DA, Asafu-Adjaye EB, Ellison CD, Doddapaneni S, Uppoor RS, Khan MA.

AAPS J. 2008 Jun;10(2):360-2. doi: 10.1208/s12248-008-9046-3. Epub 2008 Jul 1. No abstract available.

16.

The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs.

Uppoor RS, Mummaneni P, Cooper E, Pien HH, Sorensen AG, Collins J, Mehta MU, Yasuda SU.

Clin Pharmacol Ther. 2008 Jul;84(1):69-74. doi: 10.1038/sj.clpt.6100422. Epub 2007 Nov 21.

PMID:
18563070
17.

Improving pediatric dosing through pediatric initiatives: what we have learned.

Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, Gieser G, Di Giacinto J, Huang SM, Lee P, Mathis L, Murphy D, Murphy S, Roberts R, Sachs HC, Suarez S, Tandon V, Uppoor RS.

Pediatrics. 2008 Mar;121(3):530-9. doi: 10.1542/peds.2007-1529.

PMID:
18310202
18.

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.

Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta MU, Gobburu JV.

AAPS J. 2005 Oct 7;7(3):E503-12. Review.

19.

Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities.

Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VH, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I, Zhang G.

J Pharm Sci. 2004 Jun;93(6):1375-81. No abstract available.

PMID:
15124197
20.

The antioxidant system beta-D(+) glucose-glucose oxidase-catalase: tests for pyrogenicity and antigenicity.

Uppoor R, Niebergall PJ, James ER.

Pharm Dev Technol. 2001;6(1):31-8.

PMID:
11247273
21.

In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997.

Marroum PJ, Uppoor RS, Parmelee T, Ajayi F, Burnett A, Yuan R, Svadjian R, Lesko LJ, Balian JD.

Clin Pharmacol Ther. 2000 Sep;68(3):280-5.

PMID:
11014409
22.

Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate.

Mahayni H, Rekhi GS, Uppoor RS, Marroum P, Hussain AS, Augsburger LL, Eddington ND.

J Pharm Sci. 2000 Oct;89(10):1354-61.

PMID:
10980510
23.

In vitro metabolic interaction studies: experience of the Food and Drug Administration.

Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, Marroum P.

Clin Pharmacol Ther. 1999 Jul;66(1):9-15.

PMID:
10430104
24.

Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.

Eddington ND, Marroum P, Uppoor R, Hussain A, Augsburger L.

Pharm Res. 1998 Mar;15(3):466-73. Erratum in: Pharm Res 1998 Aug;15(8):1320.

PMID:
9563079
25.

beta-D(+) glucose-glucose oxidase-catalase for use as an antioxidant system.

Uppoor R, Niebergall PJ.

Pharm Dev Technol. 1996 Jul;1(2):127-34.

PMID:
9552339

Supplemental Content

Loading ...
Support Center